Skip to content

Interlaminar epidural platelet rich plasma versus epidural steroid injection for acute herpes zoster: a prospective clinical evaluation

Interlaminar epidural platelet rich plasma versus epidural steroid injection for acute herpes zoster: a prospective clinical evaluation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104894
Enrollment
Unknown
Registered
2025-06-25
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-herpetic neuralgia

Interventions

Epidural PRP group:After the patient meets the inclusion/exclusion criteria, the supervising physician will explain in detail to the patient the principles, procedures, expected effects, and potential

Sponsors

Renji Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with herpes zoster, 2 weeks or more of onset, over 18 years of age, NRS score of >=5, blisters in the thoracolumbar segment, and the ability to give informed consent.

Exclusion criteria

Exclusion criteria: (1) The patient requires surgical intervention; (2) Cervical shingles and trigeminal shingles; (3) Bilateral herpes zoster; (4) Coagulation dysfunction (platelet count less than 100,000/mL, international normalized ratio [INR] greater than 1.5); (5) Use of anticoagulant and/or antiplatelet drugs (excluding aspirin); (6) Have received epidural steroid injections within the past year; (7) Systemic infection; (8) Allergies: contrast agents, steroids, PRP, local anesthetics; (9) The body cannot tolerate epidural injection; (10) Uncontrolled mental disorders; (11) History of drug abuse (including alcoholic opioids); (12) Known severe immune disorder (e.g., AIDS); (13) Patients requiring steroid therapy; (14) Severe skin rash (no skin area suitable for injection); (15) Pregnant/lactating; (16) Patient refusal.

Design outcomes

Primary

MeasureTime frame
NRS Score;

Secondary

MeasureTime frame
SF-12;DASS;Analgesic medication demand;

Countries

China

Contacts

Public ContactYinhui Fan

Renji Hospital, Shanghai Jiao Tong University School of Medicine

fanyinghui@renji.com+86 138 0190 0088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026